Sign Up
Stories
Clinical Trial Controversies Spark Investor Actions
Share
Amgen and Pfizer Complete Acquisitions b...
Amgen to Lay Off Horizon Employees After...
Assertio Holdings Faces Securities Law I...
AlloVir Faces Securities Fraud Lawsuit
Assertio Faces Lawsuit Amid Stock Declin...
Assertio Holdings Faces Securities Lawsu...
Overview
API
Investors are taking legal action against AlloVir and BioVie for alleged misconduct in clinical trials, leading to share price declines and financial losses.
Ask a question
How might the outcomes of these legal actions impact the reputation and future operations of AlloVir and BioVie?
In what ways can regulatory bodies enhance oversight to prevent scientific misconduct and protect investor interests?
What measures can companies take to ensure transparency and compliance in clinical trials to avoid similar investor backlash?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Feb 2024
Coverage